Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Deferoxamine pharmacokinetics.

J B Porter1

  • 1Department of Haematology, University College of London, England.

Seminars in Hematology
|February 24, 2001
PubMed
Summary
This summary is machine-generated.

Pharmacokinetic studies of deferoxamine are limited, especially in sickle cell disorder patients. Measuring deferoxamine metabolites may help prevent excessive dosing in iron-overloaded patients.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Technical Report: Triple-Colour Staining Flow Cytometry for Co-Distribution of Thrombospondin Receptor (CD36), Ribonucleic Acid (RNA) and Fetal Haemoglobin (HbF) in Sickle Red Blood Cells.

Hematology (Amsterdam, Netherlands)·2016
Same author

Raised haematocrit concentration and the risk of death and vascular complications after major surgery.

The British journal of surgery·2013
Same author

Efficacy and safety of deferasirox at low and high iron burdens: results from the EPIC magnetic resonance imaging substudy.

Annals of hematology·2012
Same author

Reversal of cardiac iron loading and dysfunction in thalassemic mice by curcuminoids.

Medicinal chemistry (Shariqah (United Arab Emirates))·2011
Same author

Quality of life in thalassemia: a comparison of SF-36 results from the thalassemia longitudinal cohort to reported literature and the US norms.

American journal of hematology·2010
Same author

Rapid flow cytometric quantitation of reticulated platelets in whole blood.

Platelets·2010
Same journal

Pain in SCD-Many mechanisms and mysteries.

Seminars in hematology·2026
Same journal

The many facets of cardiopulmonary complications in sickle cell disease.

Seminars in hematology·2026
Same journal

Clonal hematopoiesis in the setting of sickle cell disease and its relevance to curative therapies.

Seminars in hematology·2026
Same journal

Treatment of myeloproliferative neoplasms: Exploring new horizons of who and when to cytoreduce in patients with polycythemia vera and essential thrombocytosis.

Seminars in hematology·2026
Same journal

Telomeres biology disorders: the past, the present and the future.

Seminars in hematology·2026
Same journal

Cardiovascular complications in patients with myeloproliferative neoplasms: What hematologists need to know.

Seminars in hematology·2026
See all related articles

Area of Science:

  • Pharmacology and Therapeutics
  • Hematology
  • Clinical Chemistry

Background:

  • Deferoxamine (DFO) has been used clinically for over 25 years for iron chelation therapy.
  • Limited pharmacokinetic (PK) data exists for DFO, particularly in specific patient populations like those with sickle cell disorders (SCD).
  • Iron overload is a growing concern in SCD patients due to chronic transfusions.

Purpose of the Study:

  • To review existing pharmacokinetic and metabolism studies of deferoxamine.
  • To highlight the need for explicit PK studies in sickle cell disorder patients.
  • To explore the potential of metabolite levels as indicators of DFO dosing.

Main Methods:

  • Review of published pharmacokinetic and metabolism studies of deferoxamine in various patient groups (healthy volunteers, hereditary hemochromatosis, beta-thalassemia).

Related Experiment Videos

  • Analysis of deferoxamine and ferrioxamine concentrations in plasma.
  • Assessment of deferoxamine metabolite levels in relation to dosing and clinical status.

    • Main Results:

    • Early studies showed similar peak DFO concentrations but higher ferrioxamine in transfusional overload patients vs. healthy volunteers.
    • In beta-thalassemia, continuous IV DFO infusion showed a half-life of 0.28 h and steady-state concentration of 7 micromol/L.
    • Higher plasma metabolite proportions correlated with lower serum ferritin relative to DFO dose, suggesting potential for excessive dosing.

    Conclusions:

    • Serum ferritin is an unreliable marker for iron overload in SCD.
    • Measuring deferoxamine metabolites or the DFO/ferrioxamine ratio may help identify patients at risk of excessive DFO dosing.
    • Urgent pharmacokinetic and metabolism studies of deferoxamine are needed in sickle cell disorder patients.